Program
ezabenlimab
Also written as “Ezabenlimab” and “BI 754091”.
In Boehringer Ingelheim's pipeline, PD-1 antibody
. Its studies are mostly in Neoplasms · Small Cell Lung Carcinoma · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 132 open or running | phase 3since Apr 15, 2024 | Oct 31, 2016 | Mar 8, 2027phase 1 · NCT05846516 |
- Named in Boehringer Ingelheim’s own pipeline as
Ezabenlimab
, phase 1, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 31, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02952248 · 110 enrolled · United States, Canada, United Kingdom
- May 23, 2017Phase 1 study in NeoplasmsNCT03166631 · 62 enrolled · United States
- Feb 9, 2018Early phase 1 study in NeoplasmsNCT03433898 · 146 enrolled · Japan, South Korea, Taiwan
- Nov 26, 2018Phase 1 study in Carcinoma, Non-Small-Cell LungNCT03780725 · 8 enrolled · Netherlands
- May 24, 2019Phase 1 study in NeoplasmsNCT03964233 · 119 enrolled · United States, Australia, Belgium and more
- Oct 30, 2019Phase 1 study in NeoplasmsNCT04147234 · 42 enrolled · United States, Spain, United Kingdom
- Aug 3, 2020Phase 2 study in Anal Canal Squamous Cell CarcinomaNCT04499352 · Korea, Republic of
- Nov 27, 2020Phase 1 study in Solid TumorsNCT04653142 · 18 enrolled · Japan
- Feb 10, 2022Phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT05249426 · 48 enrolled · United States, France, Japan and more
- Jul 1, 2022Phase 1 study in Colorectal NeoplasmsNCT05446129 · 2 enrolled · United States
- Apr 18, 2023Phase 1 study in Pancreatic Ductal AdenocarcinomaNCT05846516 · 59 enrolled · United States, Germany, Spain and more
- May 25, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05879978 · 45 enrolled · Belgium, France, Germany and more
- Apr 15, 2024Phase 3 study in Histiocytoma, Malignant FibrousNCT06370871
Ahead
- Mar 8, 2027Primary completion: phase 1 study in Pancreatic Ductal AdenocarcinomaNCT05846516
TargetBeta
“PD-1 antibody”the company's pipeline, read by Claude · source
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
| sasanlimab | Pfizer | phase 3 | 4 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06370871Histiocytoma, Malignant Fibrous | 3 | Withdrawn | Jul 3, 2026 | 0 |
| NCT05879978Small Cell Lung Carcinoma · Belgium, France, Germany and more | 1 | Active, not recruiting | Jun 11, 2025 | 45 |
| NCT05846516Pancreatic Ductal Adenocarcinoma · United States, Germany, Spain and more | 1 | Active, not recruiting | Mar 8, 2027 | 59 |
| NCT05446129Colorectal Neoplasms · United States | 1 | Terminated | Aug 11, 2023 | 2 |
| NCT05249426Squamous Cell Carcinoma of Head and Neck · United States, France, Japan and more | 1 | Completed | Jul 15, 2024 | 48 |
| NCT04653142Solid Tumors · Japan | 1 | Completed | Apr 20, 2022 | 18 |
| NCT04499352Anal Canal Squamous Cell Carcinoma · Korea, Republic of | 2 | Withdrawn | Oct 19, 2020 | 0 |
| NCT04147234Neoplasms · United States, Spain, United Kingdom | 1 | Completed | Nov 15, 2022 | 42 |
| NCT03964233Neoplasms · United States, Australia, Belgium and more | 1 | Completed | Sep 5, 2024 | 119 |
| NCT03780725Carcinoma, Non-Small-Cell Lung · Netherlands | 1 | Terminated | Feb 19, 2020 | 8 |
| NCT03433898Neoplasms · Japan, South Korea, Taiwan | Early 1 | Completed | Jul 20, 2023 | 146 |
| NCT03166631Neoplasms · United States | 1 | Terminated | Sep 15, 2020 | 62 |
| NCT02952248Neoplasms · United States, Canada, United Kingdom | 1 | Completed | Apr 30, 2021 | 110 |
How it is read
Names in the registry
- “Ezabenlimab”, 6 entries
- “BI 754091”, 6 entries
- “ezabenlimab”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 5 studies
- Small Cell Lung Carcinoma, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.